Chinese medicine consisting of different herbal medicines, has been used for centuries in the treatment of muscular spasticity following stroke, epilepsy or spinal cord injury. However, the precise mechanisms involved remain poorly understood. In the present study, we investigated the neuroprotective effects of GLGZD on glutamate-induced apoptosis in cultured BV-2 cells, as well as the underlying mechanisms. A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was applied to assess the viability of the cells. An Annexin V/propidium iodide (PI) assay was utilized to analyze cellular apoptosis. Mitochondrial membrane potential (MMP) was evaluated by flow cytometry and laser scanning confocal microscopy. The gene and protein expression of the apoptosis-related genes, Bcl-2 and Bax, was analyzed by RT-PCR and western blot analysis, respectively. Furthermore, the expression of cleaved caspase-3 protein was detected by immunofluorescence. Glutamate treatment induced the loss of BV-2 cell viability, which was associated with an increase in the apoptotic rate, as well as an increase in the Bax/Bcl-2 ratio and the extracellular levels of cleaved caspase-3. Treatment with GLGZD significantly reversed these phenotypes, with its maximum protective effects observed at the concentration of 1,000 µg/ml. These results indicate that GLGZD protects BV-2 cells from glutamate-induced cytotoxicity. These protective effects may be ascribed to its anti-apoptotic activities, in part, associated with the decrease in the Bax/Bcl-2 ratio and caspase-3 expression, as well as with the stability of high mitochondrial membrane potential.
Introduction
Microglia, the resident innate immune cells of the brain, have been suggested to play a role in host defense and tissue repair in the central nervous system (CNS) and CNS-associated diseases, such as Parkinson's, Alzheimer's and Huntington's diseases (1) . BV-2 cells are a common microglial cell line that has been widely used to study inflammatory and necrotic reactions during the course of neurological diseases (2) (3) (4) .
Traditional Chinese Medicine (TCM), which has a history of more than three thousand years, is based on treatments using compounds extracted from the natural environment (plants). There are many herbal prescriptions for the treatment of CNS-associated diseases. Gua Lou Gui Zhi decoction (GLGZD), consists of extracts of Trichosanthis Radix, Ramulus Cinnamomi, Paeonia lactiflora, Glycyrrhiza, Zingiber officinale Roscoe and Fructus Jujubae (5) (6) (7) . This treatment has been formulated from the time of the Eastern Han Dynasty (25-220 AD), and has typically been used in the treatment of muscular spasticity following stroke, epilepsy, or spinal cord injury (5) (6) (7) . However, the precise mechanisms responsible for its neuroprotective and anti-spasticity effects remain poorly understood.
Neuronal apoptosis, a form of programmed cell death that may serve in the regulation of nervous system development, is an important mechanism of neuronal death in many models of acute and chronic neurological disorders (8, 9 ). Glutamate, a major excitatory amino acid neurotransmitter in the CNS, mediates several physiological processes by engaging the ionotropic glutamate receptor and the metabotropic glutamate receptor (10) . However, dysfunction of these glutamate transporters may be a major contributing factor to the increase in extracellular glutamate concentration and resulting excitotoxicity. Furthermore, the excess stimulation of glutamate receptors can induce neuroinflammation and eventual neurodegeneration (11) . Therefore, glutamate toxicity has been implicated in several acute and chronic neurological disorders, such as cerebral ischemia, stroke, epilepsy, Alzheimer's disease and Parkinson's disease (1, (10) (11) (12) (13) .
Thus, in this study, we used glutamate to induce damage to BV-2 cells, and investigated the protective effects of GLGZD on this cell model, as well as the underlying mechanisms involved. After the first decoction (2 h), the suspension was filtered and water was added for the second decoction (1 h). The filtered and mixed suspension from the two decoctions was concentrated under vacuum by using a rotary evaporator to a final concentration of 1.16 g/ml. The samples were then stored at -20˚C before use.
Neuroprotective effects of Gua Lou Gui
Cell culture and treatments. The cells were cultured in DMEM/high glucose medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml streptomycin solution at 37˚C under an atmosphere of 5% CO 2 (Thermo Fisher Scientific, Waltham, MA, USA). One day prior to treatment, the culture medium was changed to DMEM/high glucose medium with 0.5% FBS in order to reduce the serum effect. Twenty-four hours after seeding, the medium was renewed with one of the three types of fresh culture medium (medium without glutamate, with 30 mM glutamate, and 30 mM glutamate plus various concentrations of GLGZD), and incubated for 24 h. In a single experiment each treatment was performed in triplicate.
Cell viability. Cells were seeded into 96-well plates at a concentration of 5-6x10 4 cells/ml. Cell viability was evaluated with a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The MTT assay was performed as follows: 20 µl of 5 mg/ml MTT dissolved in phosphate-buffered saline (PBS) was added to each individual well followed by incubation at 37˚C for 4 h. The solution was then removed, and the produced formazan was solubilized in 100 µl dimethyl sulfoxide (DMSO). Absorbance was measured at 570 nm using an automated microplate reader (Bio-Rad Laboratories, Hercules, CA, USA). Cell viability was expressed as a percentage of the control culture value.
Analysis of cell morphology. Cells were seeded into 6-well microplates. Following treatment for 24 h, the cells were fixed for 10 min with 4% paraformaldehyde in PBS, washed with PBS, then visualized and photographed under a phase contrast microscope (Leica, Wetzlar, Germany). 
Analysis of apoptosis.

Analysis of mitochondrial membrane potential (MMP).
The JC-1 assay kit (KeyGen Biotech) was employed to measure the MMP of BV-2 cells according to the manufacturer's instructions. Briefly, the cells were seeded into 6-well plates and exposed to glutamate or GLGZD for 24 h. Thereafter, the cells were harvested and resuspended in a mixture of 500 µl culture medium and 500 µl JC-1 staining fluid, and incubated in the dark at 37˚C for 20 min. Following two washes with JC-1 staining buffer and incubation in DMEM, the cells were analyzed by flow cytometry. Mitochondria containing red JC-1 aggregates in healthy cells were detectable in the FL-2 channel, and those containing green JC-1 monomers in apoptotic cells were detectable in the FL-1 channel. The values of MMP staining from each sample were expressed as the ratio of red fluorescence intensity over green fluorescence intensity.
We also evaluated the MMP of BV-2 cells in situ. The cells were seeded in a glass-bottom cell sterile culture Petri dish specific for confocal microscopy (diameter of 15 mm, Nest Biotechnology Co., Ltd., Shanghai, China) for 24 h. Following 24 h of treatment with glutamate or GLGZD, the cells were incubated with a mixture of 500 µl JC-1 staining fluid and 500 µl cell culture medium in the dark at 37˚C for 30 min. Subsequently, the cells were washed twice with staining buffer preserved in 4˚C. Lastly, 1 ml of cell culture medium was added to each specimen and the cells were analyzed using a LSM 710 laser scanning confocal microscope (Carl Zeiss, Oberkochen, Germany).
Analysis of mRNA expression by reverse transcription polymerase chain reaction (RT-PCR).
Total RNA was isolated using TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the supplier's instructions. RNA was quantified by optical density measurements at 260 and 280 nm. Integrity was confirmed by 1% agarose gel electrophoresis. We used 2 µg of RNA in a 20 µl reaction mixture utilizing M-MLV reverse transcriptase (Fermentas, Waltham, MA, USA) according to the supplier's instructions. The resultant reverse transcription products were stored at -20˚C until further use. Mouse polymer, Bcl-2 and Bax primers were synthesized by Shanghai Sangon Biological Engineering Technology and Services Co., Ltd. (Shanghai, China) according to the following sequences: Bax sense, 5'-GAGACACCTGA GCTGACCTTG-3' and antisense, 5'-GAAGTTGCCATCAG CAAACAT-3'; Bcl-2 sense, 5'-ATGTGTGTGGAGAGCGT CAAC-3' and antisense, 5'-CAGCCAGGAGAAATCAAA CAG-3'; β-actin sense, 5'-GAGACACCTGAGCTGACC TTG-3' and antisense, 5'-GAGACACCTGACCACCCTG TTGCTGTA-3'. The product size for Bax, Bcl-2 and β-actin sense was 195, 177 and 490 bp, respectively. PCR was carried out with Taq polymerase (Thermo Fisher Scientific Inc., Rockford, IL, USA) according to the supplier's instructions. The PCR conditions were as follows: 94˚C for 4 min, followed by 35 cycles (30 for β-actin) of 1 min denaturation at 94˚C, 1 min annealing at 58˚C, 1 min polymerization at 72˚C, and finally 10 min extension at 72˚C. The PCR products were analyzed by 1.5% agarose electrophoresis and visualized using ethidium bromide (0.25 µg/ml) in 0.5X TBE buffer (Tris 40 mM, EDTA 1 mM, boric acid 44 mM) at 80 V (constant voltage). Images of gels were acquired and analyzed by Molecular Imager software (Bio-Rad Laboratories). The density of the PCR bands was expressed as a ratio of the band density divided by that of the housekeeping gene, β-actin.
Western blot analysis of protein expression. Cells were harvested and lysed in RIPA buffer containing the protease inhibitor, phenylmethylsulfonyl fluoride (PMSF) (both from Beyotime, Shanghai, China). Cell lysates were collected by centrifugation at 12,000 x g for 10 min at 4˚C. Protein concentrations were determined using an enhanced BCA protein assay kit (Beyotime). Equal amounts of protein from each sample (40 µg) were resolved by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (12%) and transferred onto PVDF membranes. The membranes were incubated in blocking buffer (non-fat milk) and then incubated overnight at 4˚C with rabbit polyclonal antibodies against Bax (CST, 1:1,000, 20 kDa), Bcl-2 (CST, 1:1,000, 26 kDa) or β-actin (1:4,000, 43 kDa) (Beyotime). The membranes were stringently washed and incubated with HRP-conjugated secondary antibodies (Proteintech Group, Chicago, IL, USA), for 1 h at room temperature. After washing, proteins were detected using enhanced chemiluminescence, and images were acquired using a Bio-Image Analysis System (Bio-Rad Laboratories).
Detection of cleaved caspase-3 protein by immunofluorescence. Cells were seeded in a glass-bottom cell sterile culture Petri dish specific for confocal microscopy (diameter of 15 mm, Nest Biotechnology Co., Ltd.) for 24 h. Following treatment with glutamate or GLGZD (125, 250, 500 and 1,000 µg/ml) for 24 h, the cells were fixed with 4% formaldehyde in PBS for 30 min at room temperature, rinsed three times in PBS, and incubated in blocking buffer (5% BSA, 10% normal donkey serum, 0.3% Triton X-100 in PBS) for 60 min at room temperature. The cells were then incubated with cleaved caspase-3 antibody (Alexa Fluor 488-conjugated) overnight at 4˚C (CST, 1:100). The cells were washed twice with PBS, and incubated with a rhodamine-conjugated phalloidin (F-actin) antibody (cytoskeleton, 1:100) at 37˚C for 30 min. Lastly, DAPI (Beyotime, 1:1,000) was added to each specimen for nuclei staining and the cells were analyzed using a LSM 710 laser scanning confocal microscope under a x40 water objective (Carl Zeiss).
Statistical analysis. Data are expressed as the means ± standard error of mean (SEM). Data were first analyzed using Portable IBM SPSS Statistics software. A paired-sample t-test was then performed to compare the treated samples, and values of P<0.05 were considered to indicate statistically significant differences.
Results
Total phenolic compound and sugar content in the extract. In our previous study (6), a high-performance liquid chromatography (HPLC) fingerprint was used to control the quality of the GLGZD extract, which revealed that the method we use to prepare GLGZD was efficient and that the product used for this study was pure.
Effect of GLGZD on viability and apoptosis in glutamatestimulated BV-2 cells.
In order to evaluate the effects of GLGZD on glutamate-induced cell death, we first determined the optimal concentration of glutamate which was able to induce BV-2 cell death (Fig. 1A) . Increasing concentrations of glutamate were added (15, 20, 25, 30 , 35 and 40 mM) and cell survival was measured. The concentration of glutamate that induced approximately 50% cell death, and the appropriate concentration for our experiments, was 30.0 mM.
The glutamate-induced loss of cell viability was markedly attenuated by treatment with GLGZD (Fig. 1B) . Following treatment with 30 mM glutamate for 24 h, cells survived for an average of 41.72±6.95% of the control value. Treatment with 125, 250, 500 and 1,000 µg/ml of GLGZD in the presence of 30.0 mM glutamate markedly increased cell viability to 51.37±5.99, 53.24±3.68, 58.02±4.34 and 58.39±4.81%, respectively. These results demonstrated that the glutamate-induced loss of cell viability was partially attenuated by GLGZD in a dose-dependent manner. In addition to cell viability, we also sought to analyze the morphological characteristics of BV-2 cells cultured in the presence of glutamate with or without GLGZD. BV-2 cells display a characteristic small spherical morphology with more than half of the cells displaying process-bearing sites, often bipolar and tripolar ( Fig. 2A) . The addition of 30 mM glutamate induced contraction, rounding and even floating of the majority of cells (Fig. 2B) . This suggests the involvement of microglial cell apoptosis and necrosis induced by treatment with glutamate. This morphological change was effectively inhibited by 250, 500 and 1,000 µg/ml of GLGZD (Fig. 2D-F) .
A quantitative evaluation of apoptosis was then carried out by flow cytometry with an Annexin V/PI test. The apoptotic rate of the cells treated with 30 mM glutamate alone for 24 h markedly increased to 36.46% (Fig. 3) . However, treatment with GLGZD reversed this effect. The proportion of apoptotic cells decreased from 36.46% to 24.86, 19.32, 17.11 and 16.06%, when the cells were co-incubated with concentrations of 125, 250, 500 and 1,000 µg/ml of GLGZD, respectively (Fig. 3A-F) . A dose-dependent effect was evident, as the highest concentration of GLGZD (1,000 µg/ml) demonstrated the least number of apoptotic cells (Fig. 3G) . 
Effects of GLGZD on MMP in glutamate-stimulated BV-2 cells.
Apoptosis is often accompanied by mitochondrial dysfunction, and the decline in MMP is considered as a symbolic event of early cellular apoptosis (14, 15) . In this study, to investigate the effects of glutamate and GLGZD on mitochondrial function, indicators of mitochondrial activity were monitored using JC-1 staining. The MMP of BV-2 cells treated with glutamate for 24 h was markedly reduced (Fig. 4) . The ratio of aggregated JC-1 (FL-2 channel) to monomeric JC-1 (FL-1 channel) was decreased from 79.8 (control group) to 33.7% (glutamatetreated only group) (P<0.01) after 24 h of treatment. When the cells were incubated with 125, 250, 500 and 1,000 µg/ml of GLGZD, the ratio increased from 33.7% to 42.7, 54.5, 78.4 and 79.7%, respectively (Fig. 4A-F) . Treatment with GLGZD attenuated the decline in MMP in a dose-dependent manner, as indicated by the increase in red (JC-1 aggregates)/green (JC-1 monomers) ratio (Fig. 4G) .
In addition, the BV-2 cells stained with JC-1 exhibited mitochondrial red fluorescence with a little green fluorescence, suggesting that the cells were in a normal polarized state (Fig. 5A) . The JC-1 aggregates were dispersed to the monomeric form (green fluorescence) in the glutamate-treated cells (Fig. 5B) . However, treatment with GLGZD attenuated the dissipation of the MMP (Fig. 5C-F) , corroborating our results from flow cytometry (Fig. 4) . , (B) glutamate (Glu), (C) Glu + GLGZD (125 µg/ml), (D) Glu + GLGZD (250 µg/ml), (E) Glu + GLGZD (500 µg/ml), (F) Glu + GLGZD (1,000 µg/ml).
Effects of GLGZD
To determine whether GLGZD protects the BV-2 cells from glutamate-induced apoptosis by modulating the Bcl-2 family of proteins, the mRNA and protein levels of Bax and Bcl-2 were estimated using RT-PCR and western blot analysis. We detected an increase in Bax and a decrease in Bcl-2 mRNA levels following exposure to glutamate (Fig. 6A and B) . Treatment with GLGZD inhibited the upregulation of Bax and enhanced the upregulation of Bcl-2 slightly at 24 h of glutamate exposure. Thus, GLGZD attenuated the increase in the Bax to Bcl-2 ratio induced by glutamate, a sign of apoptosis inhibition. In addition to the GLGZD modulation of Bax and Bcl-2 mRNA levels, we observed similar results with the protein levels ( Fig. 6C and D) .
Effects of GLGZD on the expression of cleaved caspase-3 protein in glutamate-stimulated BV-2 cells. We utilized an antibody specific for the activated form of caspase-3, a caspase that plays an important role in a number of neuronal apoptotic pathways, as an 'executioner' of cell death (16) . Treatment with glutamate led to the formation of apoptotic nuclei, as assessed by an abundance of green puncta labeled with the antibody to activated caspase-3 (Fig. 7) . Cleaved caspase-3 was localized in the nuclei, as it overlapped with apoptotic cell nuclei. Treatment with GLGZD induced the re-localization of caspase-3, out of the nucleus, representing a decrease in caspase-3 expression levels ( Fig. 7) 
Discussion
Increasing evidence indicates that a number of herbal medicinal plants, including some formulations used in TCM, have beneficial effects on neurodegenerative diseases, such as Artemisia annua L. (17), baicalein (2, 14) , cassia twig (18), 6-Shogaol (a ginger product) (19) , Gastrodia elata Blume. (20) , Chrysanthemum indicum Linné (21), pinocembrin (11), Buyang Huanwu decoction (22) , Guizhi-Fuling capsules (23), Xiao-Xu-Ming decoction (24), Danggui-Shaoyao-San (25) and Yi-Gan San (13) . Similar to other Chinese medicinal compounds, GLGZD is thought to possess various traditional and ethnopharmacological benefits for neurodegenerative diseases, and it has long been clinically employed in the treatment of stroke (5) . Although the underlying mechanisms remain largely unknown, a rat model of focal cerebral ischemia-reperfusion (I/R) injury demonstrated that GLGZD exerts neuroprotective and anti-spasticity effects in a model of cerebral ischemia through the modulation of glutamate levels and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor expression (6) . In addition, GLGZD has been shown to induce an anti-inflammatory response through the suppression of the LPS-stimulated TLR4/NF-κB pathway in BV-2 murine microglial cells (7) . However, molecular studies on cellular models of toxin-based Parkinson's disease have suggested that oxidative stress-mediated mitochondrial dysfunction, apoptosis and microglial-mediated neuroinflammation play a major etiological role in neurotoxicity (26) . Therefore, in the present study, we focused on the ability of GLGZD to suppress neurodegeneration and neuroinflammation in a cellular model of glutamate-induced apoptosis and to explore the intrinsic mechanisms involved.
We examined the neuroprotective effects of GLGZD on the glutamate-induced apoptosis of BV-2 cells. Glutamate significantly decreased cell viability and increased cell apoptosis. An MTT assay and an Annexin V/PI test revealed that GLGZD markedly inhibited the glutamate-induced apoptosis of BV-2 cells. The Annexin V/PI test results revealed that glutamate increased early and late apoptosis; however, treatment with GLGZD suppressed the percentage of early apoptotic cells.
Genes of the Bcl-2 family play a key role in the mitochondrial pathway of apoptosis, reflecting the balance between the pro-and anti-apoptotic members of the Bcl-2 family, of which Bax and Bcl-2 are the two main members (27) . In this study, we found that glutamate had a profound effect on the gene expression and protein levels of Bax and Bcl-2. Our results indicated that GLGZD provided neuroprotection partly by inhibiting Bax overexpression and increasing anti-apoptotic Bcl-2 expression. Treatment with GLGZD reduced the expression of pro-apoptotic Bax and increased the expression of anti-apoptotic Bcl-2 significantly in a dose-dependent manner, thereby attenuating the elevated glutamate-induced Bax/Bcl-2 ratio in the BV-2 cells. This finding indicate that the protective effects of GLGZD against neurological damage are likely attributed to its anti-apoptotic properties.
Caspases are cysteine proteases that are essential for apoptosis in a variety of in vitro and in vivo models. Caspase-3 is the major executioner protease, responsible for initiating the mitochondrial-regulated apoptotic program (16, 27, 28) . We found that the levels of caspase-3, which is normally expressed at low levels, increased significantly when the cells were treated with glutamate for 24 h. However, following treatment with GLGZD, the increased expression levels of caspase-3 were slightly lower, and these changes occurred in a dosedependent manner.
The activation of microglial cells plays a crucial role in the initiation and progression of brain inflammation, and BV-2 cells have been used to study the expression of various proinflammatory and anti-inflammatory cytokines (8) . Although in a previous study, we revealed that GLGZD exhibited an antiinflammatory response on LPS-induced BV-2 cell damage (7), it remains unknown whether the pro-apoptotic effects of glutamate are due to the excitotoxic properties of pro-inflammatory cytokines or to the direct activation of microglial phagocytosis (4). Therefore, the similarity and differences between the possible anti-apoptotic and anti-inflammatory mechanisms of GLGZD on microglial cells require further investigation.
In conclusion, GLGZD exerts protective effects against glutamate-induced cellular injury. To our knowledge, this is the first report revealing the role of GLGZD in protecting BV-2 cells against glutamate-induced neurotoxicity. Further studies on mature primary neurons, as well as on animal models of Parkinson's disease and comparisons with known anti-parkinsonian agents are, however, required to establish both efficacy and safety. Based on the protective effects of GLGZD on glutamate-induced cellular injury, GLGZD may be used as a potential therapeutic candidate for the treatment of neurodegenerative disorders.
